Integral Health Puts $91 M on Vera Therapeutics Ahead of July FDA Decision
Integral Health Asset Management increased its Vera Therapeutics holding by 100,000 shares, bringing its stake to $91.15 million (4.5% of its AUM). The move comes as Vera awaits a July 7 FDA decision on its lead drug atacicept, a catalyst that could trigger a rapid commercial rollout.
DNA-Engineered Silver Nanoclusters Enable Precision Killing of Drug-Resistant Bacteria
A team led by Kirill Afonin at UNC Charlotte engineered programmable DNA scaffolds that organize silver nanoclusters into highly potent antimicrobial agents. The spatially arranged DNA‑AgNCs showed up to 78‑fold greater killing efficiency against ESKAPE pathogens and meningitis‑causing bacteria compared...
Glenmark Launches GLIPIQ for Type 2 Diabetes in India
Glenmark Pharmaceuticals has launched GLIPIQ, a semaglutide‑based GLP‑1 therapy, in India following CDSCO approval after a local Phase III study. The product is offered in both vial‑with dose‑specific syringes and pre‑filled pen formats, covering 2 mg, 4 mg and 8 mg strengths. Pricing is...
Study Finds FGFR1 Boosts Cholesterol Uptake in Prostate Cancer Cells
Researchers at Texas A&M Health discovered that the fibroblast growth factor receptor 1 (FGFR1) drives cholesterol accumulation in prostate cancer cells by activating the sterol regulatory element‑binding protein 2 (SREBP2). This signaling cascade up‑regulates LDL‑receptor (LDLR) and cholesterol‑synthesis enzymes, boosting intracellular cholesterol...
We’re on the Brink of Self‑directed Human Evolution
When I was talking to Sergiy Velychko, a former postdoc from George Church's lab, about the future of human genome engineering, we discussed: “We're now at this point where we can engineer ourselves. We can do stem cell therapies. We can...
Aelis Farma Announces the Successful Start of the Recruitment of the Phase 2B Clinical Trial with AEF0217 for the Treatment...
Aelis Farma announced that recruitment has begun for its Phase 2B trial of AEF0217, a first‑in‑class signalling‑specific CB1 receptor inhibitor, aimed at treating behavioral and cognitive impairments in Down syndrome. The study will enroll 188 participants aged 16‑32 across ten...
Lab Celebrates Progress While Students Head to Grad School
Celebrating another week of amazing progress at the Sinclair lab and farewell to a couple of our beloved students, Yifan and Hanyu, both headed off to graduate school 👩🏻🎓 This morning we had our usual three hour lab meeting, but it...
Contaminated Cell Line Turns Liver Cancer Papers Retracted
1/ A researcher spent 2 years studying liver cancer biology. Published 3 papers. Then discovered the "liver cancer" cell line was actually HeLa -- a cervical cancer line that contaminated their stock decades ago. Those papers? Retracted. https://t.co/q3a9g0G04s
What Is Flumist, the New Flu Vaccine for Kids That's Sprayed in Their Noses?
Australia will introduce FluMist, a needle‑free nasal flu vaccine for children aged 2‑17, this winter. The live‑attenuated spray targets the upper respiratory tract and offers protection comparable to injectable shots, reducing flu cases by 40‑60%. It will be free for...
SIRT1: Longevity Gene Proven to Suppress Cancer
Fun fact: in 2008, when we published that NAD-dependent SIRT1 suppresses cancer, almost no one believed us. How could a longevity gene suppress cancer? they asked https://t.co/aPAG3zf470
Senolytics May Harm Brain Myelin, Use Supplements Cautiously
It's studies like this why I treat supplements are a secondary, and last resort, not a primary approach Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum https://t.co/t3jMFTcKcL
GSK's Lynavoy Secures FDA Approval as First U.S. Therapy for PBC Itch
GlaxoSmithKline (GSK) announced FDA approval for Lynavoy, the first U.S. drug targeting cholestatic pruritus in adults with primary biliary cholangitis (PBC). The decision rests on Phase 3 GLISTEN trial data showing rapid, sustained itch relief and improved sleep, marking the...
Comprehensive Single-Cell Transcriptomic Atlas of Microglia in Alzheimer’s Disease Mouse Models
A new study delivers a comprehensive single‑cell transcriptomic atlas of microglia from multiple Alzheimer’s disease mouse models. By profiling thousands of cells, researchers uncovered diverse microglial states, including disease‑associated subtypes linked to TREM2 signaling and amyloid pathology. The atlas integrates...
LINC01116 Binds CPS1 to Regulate Urea Cycle Function, Thereby Promoting Progression and Chemoresistance in Osteosarcoma
The study reveals that the long non‑coding RNA LINC01116 is markedly up‑regulated in metastatic osteosarcoma and directly binds the urea‑cycle enzyme CPS1. Disruption of the LINC01116‑CPS1 interaction impairs citrulline production, indicating a compromised urea cycle, and markedly suppresses tumor proliferation...
Low‑cost Vaccines Saved Half‑million Lives, Ignored for Joke
Seriously? I make low-cost vaccines that reached 100 million people, bypassed big pharma, didn’t make a dime, and saved 300,000-500,000 lives, and they focus on a junk food joke I made 6 years ago, this Rogan crowd, a bunch of...
FDA Drug Safety Communication: Planned Return of CardioGen-82 to Market with New Boxed Warning
On February 15, 2012, the FDA announced that Bracco Diagnostics’ CardioGen‑82 generator will re-enter the U.S. market after a voluntary recall in July 2011. The agency approved revised labeling that introduces a Boxed Warning and new “Alert Limits” for strontium‑82...
FDA Drug Safety Communication: Safety Update on Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab)
The FDA has revised the Tysabri (natalizumab) label to detail progressive multifocal leukoencephalopathy (PML) risk based on infusion count and prior immunosuppressant exposure. Data show 102 PML cases among 82,732 treated patients, with incidence rising sharply after 24 infusions. A...
'Meaningful' FDA Clearance Opens New Osteoarthritis Treatment Pathway
The FDA has granted clearance for Siemens Healthineers’ Varian radiotherapy platforms—including TrueBeam, TrueBeam STx, VitalBeam and Edge—to treat medically refractory osteoarthritis in adults. Low‑dose radiation therapy offers a non‑invasive alternative to steroid injections, physical therapy, and ultimately joint replacement surgery...
Letrozole vs GnRH Antagonist in Ovarian Aging IVF
A recent multicenter trial compared letrozole‑based protocols with traditional GnRH antagonist regimens for women experiencing ovarian aging undergoing IVF. The study found that letrozole reduced total gonadotropin dose and improved mature oocyte yield without compromising clinical pregnancy rates. GnRH antagonists...
EyePoint Sues Rival Ocular Therapeutix, Alleging False Claims About Eye Drug
EyePoint Therapeutics filed a lawsuit in Massachusetts accusing rival Ocular Therapeutix of spreading false and misleading statements about EyePoint’s lead experimental eye drug, Duravyu. The complaint alleges defamation, commercial disparagement, consumer‑protection violations, and interference with business relationships. EyePoint seeks a...
Chemo-Optogenetic Tool Uses Vitamin B₁₂ and Green Light to Precisely Regulate Cell Communication
Researchers at HKUST have created CarGAP, a chemo‑optogenetic system that couples vitamin B₁₂ binding with green‑light activation to toggle gap junctions on and off. In the dark, vitamin B₁₂ induces oligomerization of a bacterial CarHC domain, physically blocking connexin or innexin channels;...
Neuregulin‑2 Predicts Venetoclax Sensitivity in Non
Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma [Dec 12, 2021] Dai et al. Abstract 459 #ASH21 https://t.co/mnXEThuKgy #mmsm #PrecisionMedicine https://t.co/zx7d29Jzpk
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
ImmunityBio secured its first Asian regulatory clearance as the Macau Special Administrative Region approved ANKTIVA® for BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The decision leveraged prior FDA and EMA approvals, illustrating a...
LazySlide: Open Framework for Integrating Whole-Slide and Molecular Data
LazySlide is an open‑source Python package built on the scverse ecosystem that streamlines whole‑slide image analysis and multimodal integration. It partitions massive pathology slides into manageable patches, applies foundation AI models to extract visual features, and directly links those features...
Messenger RNA Quality Control in Aging and Age-Related Disease
Cellular health depends on rigorous quality control of messenger RNA, yet these surveillance pathways weaken with age. Research in C. elegans and yeast shows that impaired nonsense‑mediated decay, nonstop decay, and no‑go decay lead to ribosome stalling, protein aggregation, and...
Scientists Bring Mouse Brains Back to Life After “Cryosleep” Deep Freeze
Researchers at the University of Erlangen‑Nuremberg successfully revived neuronal activity in vitrified mouse brain slices after cryogenic storage. Using rapid cooling to –320 °F, they preserved synaptic membranes and long‑term potentiation for up to seven days. Electrical testing showed largely normal...
Targeting Tunneling Nanotubes Reduces Spread of Mutant Huntington’s Protein
Researchers at Florida Atlantic University discovered that the protein Rhes teams up with the bicarbonate transporter SLC4A7 to build tunneling nanotubes (TNTs) that ferry mutant huntingtin (mHTT) between neurons. Disrupting this Rhes‑SLC4A7 axis in mice dramatically curbed intercellular spread of...
FDA Approves Nivolumab Regimen as First-Line Treatment for Classical Hodgkin Lymphoma
The FDA has granted first‑line approval for a nivolumab‑plus‑AVD regimen in patients aged 12 and older with stage III‑IV classical Hodgkin lymphoma. The decision follows the phase 3 SWOG S1826 trial, which showed a 58% progression‑free survival rate and a hazard ratio of...
Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process
The FDA granted accelerated approval to Wegovy HD, a 7.2 mg weekly semaglutide injection, marking the fourth product cleared under the National Priority Voucher pilot. Phase 3 STEP UP data showed a mean 20.7% weight loss, with nearly one‑third of participants shedding 25% or...
ICAR–IVRI Achieves Breakthrough in Sahiwal Breeding Using Advanced Reproductive Technologies
The Indian Council of Agricultural Research’s Veterinary Research Institute (ICAR‑IVRI) has produced the first indigenous Sahiwal calves using ultrasound‑guided ovum pick‑up, in‑vitro fertilisation and embryo transfer (OPU‑IVF‑ET). Within five days in February‑March 2026, five healthy calves were born from a...
Early Use of Tirzepatide After Heart Attack or Stroke Linked to Key Cardiovascular Benefits
A real‑world propensity‑matched study of 1,666 non‑diabetic patients found that initiating tirzepatide within 14 days of an acute myocardial infarction or ischemic stroke cut the risk of emergency‑room visits, hospitalizations, acute kidney injury, repeat stroke and heart‑failure admission over two...
Major Leap Towards Reanimation After Death as Mammal's Brain Preserved
Researchers at Nectome have successfully cryopreserved an entire pig brain, locking cellular activity with minimal damage. The method uses rapid vitrification to prevent ice formation, preserving neural architecture and synaptic connections. Nectome now plans to offer the service to terminally...
Understanding Public Perspectives on Direct to Consumer Pharmacogenomic Testing in the UK: A Qualitative Study
Direct‑to‑consumer pharmacogenomic testing is rapidly expanding in the UK despite the absence of a dedicated regulatory framework. A 2021 parliamentary inquiry called for stronger safeguards, but these have not been applied to PGx services. Researchers conducted focus groups with consumers...
Notices of Updates
The FDA released a series of updates between 2020 and 2026 that revise, recognize, or withdraw antimicrobial susceptibility breakpoints and standards for dozens of drugs. Recent actions include recognizing M100 MIC and disk‑diffusion breakpoints for amikacin, cefiderocol, and several beta‑lactam...
In the Clinic for March 20, 2026
The March 20, 2026 "In the Clinic" page aggregates a wide array of BioWorld snapshots, special reports, and infographics covering biopharma, medical technology, and emerging therapeutic areas. It links to daily data snapshots, market outlooks, and deep‑dive analyses such as the med‑tech...
Living-Cell Robots Gain Self-Contained Nervous Systems
Robots Made From Living Cells Get Upgraded With Their Very Own Nervous Systems https://t.co/ctQ64b45O4 https://t.co/ye1TV6VwCn
Generic Semaglutide Versions Roll Out at Prices Pegged 80% Less that Novo Nordisk’s Ozempic
Indian drugmakers Natco Pharma, Glenmark Pharmaceuticals and Eris Lifesciences are set to launch generic semaglutide on March 23, 2026, just after the drug’s patent expired. The generics are priced roughly 80% less than Novo Nordisk’s Ozempic, with Natco’s vials costing...
Earendil Labs to Scale AI-Driven Biologics Platform with $787 Million Funding
Earendil Labs announced a $787 million financing round, the largest recent capital raise for AI‑enabled drug development. The funding, led by Sanofi and the Biotech Development Fund, will be used to scale its AI‑driven biologics discovery platform, expand R&D teams, and...
FAQs on IPF Therapies: Current, Emerging, and Combination Strategies
Idiopathic pulmonary fibrosis (IPF) treatment now includes three FDA‑approved antifibrotic drugs—nerandomilast, nintedanib, and pirfenidone—each shown to slow forced vital capacity decline. Nerandomilast, approved in 2025, marks the first new IPF therapy in over a decade, while cost‑effectiveness analyses favor nintedanib...
Imatinib
Imatinib (Gleevec®/Glivec®) is an oral ATP‑competitive inhibitor of the BCR‑ABL fusion tyrosine kinase, approved by the FDA in 2001 for Philadelphia chromosome‑positive chronic myeloid leukemia and other malignancies. The drug emerged from high‑throughput screening, structure‑activity relationship optimization, and structure‑based drug...
Companies Hide Device Risks, Harm Thousands
This is a recurrent fiasco. Health care companies that now the serious risk of their device or drug but keep selling it and do not acknowledge the hazard. Until so many people are harmed. Today's front page @nytimes by @katie_thomas @bostonsci...
A Gene Carried by 99% of Humanity Raises Alzheimer's Risk Dramatically. Could Gene Therapy Correct It?
A new Nature study of 450,000 people finds that the APOE gene, particularly the APOE3 and APOE4 variants, accounts for 72‑93% of Alzheimer’s disease cases, and that 99% of the population carries at least one risk‑increasing allele. Lexeo Therapeutics is...
UK’s NICE Revisits Lilly, Eisai Alzheimer's Drugs Under New Pricing Threshold
The UK’s National Institute for Health and Care Excellence (NICE) has reopened its evaluation of Eli Lilly’s donanemab and Eisai’s lecanemab after initially rejecting them on cost grounds. A newly‑introduced cost‑effectiveness threshold of roughly £20,000 per quality‑adjusted life year (QALY)...
Biotech Godfather Stelios Papadopolous Joins Garde on Podcast
This week's Readout LOUD podcast is now available on all your favorite podcast outlets -- Stelios Papadopolous, the ‘godfather’ of biotech, in conversation with @damiangarde https://t.co/RHh5Qv9OyT via @statnews
Deubiquitinase Complex Protects Oocyte Epigenome, Fertility
Polycomb repressive-deubiquitinase complex safeguards oocyte epigenome and female fertility by restraining Polycomb activity https://t.co/M6JjHH2JG2 https://t.co/dnHknjJmJy
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor From Synnovation Therapeutics, Collegium to Acquire Azstarys From Corium Therapeutics
Novartis announced a deal worth up to $3 billion to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor aimed at hormone‑receptor‑positive, HER2‑negative breast cancer. The transaction includes $2 billion upfront and potential milestones exceeding $1 billion, with closing expected in early 2026. Collegium Pharmaceutical agreed...
Listen: NI Exclusive with Checkerspot CTO on POA Innovation
Researchers engineered the heterotrophic microalga Prototheca moriformis to produce high levels of polymethylene octadecanoic acid (POA), achieving over 50% POA of total fatty acids and roughly 20.8 g/L POA in a 1 L fed‑batch fermentation. The study, funded by Nestlé and Checkerspot,...
Engineered Bioprocess Converts CO2 Into Amino Acids at 97 Percent Efficiency
Georgia Tech researchers have unveiled a cell‑free biocatalytic platform that converts carbon dioxide into the amino acids serine and glycine with a 97% yield, the highest efficiency reported for any synthetic‑biology system. By introducing heat‑tolerant enzymes from Moorella thermoacetica and...
Tumor Whole-Genome Sequencing Influences Care in 40%+ Patients
Why should tumor whole genome sequencing (WGS) be done for cancer? In real practice of medicine study of 888 patients with solid cancers, WGS directly led to clinical consequences in over 40% @NatureMedicine https://t.co/kFho0yuLS7
Biotech Giant Earendil Labs Secures $787M Funding
Giant biotech round that hit right after I sent Pro Rata: Earendil Labs raises $787M https://t.co/NWt2bBA9Lr